{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:10:09Z","timestamp":1744722609867,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","award":["18468","18468"],"award-info":[{"award-number":["18468","18468"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-97472-8","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:29:08Z","timestamp":1744720148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-1794","authenticated-orcid":false,"given":"Stephanie","family":"Reitzinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3381-1075","authenticated-orcid":false,"given":"Thomas","family":"Czypionka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"97472_CR1","unstructured":"World Obesity Federation. Global obesity observatory. https:\/\/data.worldobesity.org\/"},{"key":"97472_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller, T. D., Bl\u00fcher, M., Tsch\u00f6p, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: Advances and challenges. Nat. Rev. Drug Discov. 21, 201\u2013223 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"97472_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/cob.12183","volume":"7","author":"E Burgess","year":"2017","unstructured":"Burgess, E., Hassm\u00e9n, P. & Pumpa, K. L. Determinants of adherence to lifestyle intervention in adults with obesity: A systematic review. Clin. Obes. 7, 123\u2013135 (2017).","journal-title":"Clin. Obes."},{"key":"97472_CR4","doi-asserted-by":"publisher","first-page":"100860","DOI":"10.1016\/j.lanepe.2024.100860","volume":"37","author":"The Lancet Regional Health \u2013 Europe","year":"2024","unstructured":"The Lancet Regional Health \u2013 Europe. Semaglutide and beyond: A turning point in obesity pharmacotherapy. Lancet Reg. Health Europe 37, 100860 (2024).","journal-title":"Lancet Reg. Health - Europe"},{"key":"97472_CR5","doi-asserted-by":"crossref","unstructured":"Nauck, M. A., Quast, D. R., Wefers, J. & Meier, J. J. GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art. Mol. Metab. 46 (2021).","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"97472_CR6","unstructured":"European Medicines Agency. Wegovy EPAR product information (2023)."},{"key":"97472_CR7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"97472_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/osp4.390","volume":"6","author":"M Lee","year":"2020","unstructured":"Lee, M. et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes. Sci. Pract. 6, 162\u2013170 (2020).","journal-title":"Obes. Sci. Pract."},{"key":"97472_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.18553\/jmcp.2022.28.7.740","volume":"28","author":"N Kim","year":"2022","unstructured":"Kim, N. et al. Cost-effectiveness analysis of semaglutide 2.4\u00a0mg for the treatment of adult patients with overweight and obesity in the United States. JMCP 28, 740\u2013752 (2022).","journal-title":"JMCP"},{"key":"97472_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/j.1550-8528.1999.tb00709.x","volume":"7","author":"FL Greenway","year":"1999","unstructured":"Greenway, F. L. et al. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes. Res. 7, 523\u2013531 (1999).","journal-title":"Obes. Res."},{"key":"97472_CR11","unstructured":"ATHIS & Gesundheitsbefragung (2019)."},{"key":"97472_CR12","unstructured":"Statistik Austria. Standard-Dokumentation Metainformationen zur Gesundenbefragung 2019. https:\/\/www.statistik.at\/fileadmin\/shared\/QM\/Standarddokumentationen\/B_1\/std_b_gesundheitsbefragung_2019.pdf (2023)."},{"key":"97472_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/014107680609900517","volume":"99","author":"M Ezzati","year":"2006","unstructured":"Ezzati, M. Trends in National and state-level obesity in the USA after correction for self-report bias: Analysis of health surveys. J. R. Soc. Med. 99, 250\u2013257 (2006).","journal-title":"J. R. Soc. Med."},{"key":"97472_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1017\/S1368980011001911","volume":"15","author":"F Gro\u00dfsch\u00e4dl","year":"2012","unstructured":"Gro\u00dfsch\u00e4dl, F., Haditsch, B. & Stronegger, W. J. Validity of self-reported weight and height in Austrian adults: Sociodemographic determinants and consequences for the classification of BMI categories. Public. Health Nutr. 15, 20\u201327 (2012).","journal-title":"Public. Health Nutr."},{"key":"97472_CR15","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino, D. et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA 325, 1414 (2021).","journal-title":"JAMA"},{"key":"97472_CR16","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/s41366-021-00788-4","volume":"45","author":"CL Haase","year":"2021","unstructured":"Haase, C. L. et al. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: Evidence from a UK primary care database. Int. J. Obes. 45, 1249\u20131258 (2021).","journal-title":"Int. J. Obes."},{"key":"97472_CR17","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1186\/s12889-024-19574-8","volume":"24","author":"S Reitzinger","year":"2024","unstructured":"Reitzinger, S. & Czypionka, T. Low-, moderate-, and high-risk obesity in association with cost drivers, costs over the lifecycle, and life expectancy. BMC Public. Health 24, 2069 (2024).","journal-title":"BMC Public. Health"},{"key":"97472_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/heapol\/czz127","author":"M Haacker","year":"2019","unstructured":"Haacker, M., Hallett, T. B. & Atun, R. On discount rates for economic evaluations in global health. Health Policy Plann. https:\/\/doi.org\/10.1093\/heapol\/czz127 (2019).","journal-title":"Health Policy Plann."},{"key":"97472_CR19","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","volume":"404","author":"I Lingvay","year":"2024","unstructured":"Lingvay, I., Cohen, R. V., le Roux, C. W. & Sumithran, P. Obesity in adults. Lancet 404, 972\u2013987 (2024).","journal-title":"Lancet"},{"key":"97472_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.2525","author":"PJ Rodriguez","year":"2024","unstructured":"Rodriguez, P. J. et al. Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2024.2525 (2024).","journal-title":"JAMA Intern. Med."},{"key":"97472_CR21","unstructured":"Bartelt, K., Mast, C., Deckert, J., Gracianette, M. & Joyce, B. Many patients maintain weight loss a year after stopping semaglutide and liraglutide. EpicResearch.org. https:\/\/epicresearchblob.blob.core.windows.net\/cms-uploads\/pdfs\/many-patients-maintain-weight-loss-a-year-after-stopping-semaglutide-and-liraglutide.pdf (2024)."},{"key":"97472_CR22","doi-asserted-by":"publisher","first-page":"1151764","DOI":"10.3389\/fphar.2023.1151764","volume":"14","author":"E Car","year":"2023","unstructured":"Car, E., Vulto, A. G., Houdenhoven, M. V., Huys, I. & Simoens, S. Biosimilar competition in European markets of TNF-alpha inhibitors: A comparative analysis of pricing, market share and utilization trends. Front. Pharmacol. 14, 1151764 (2023).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97472-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97472-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:29:12Z","timestamp":1744720152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-97472-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["97472"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-97472-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12959"}}